Current Promotions

No active promotions at the moment. Check back later for special offers!

No video available

Get in Touch

Call Now Visit Website

About

Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, "universal" influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax' ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.

Keywords

biotechnology, immunology, antigens, vaccine, influenza, universal, cellular immune response, cd8 tcell, infectious diseases, immunooncology, covid

Amenities

No amenities listed yet

Upcoming Events

No upcoming events scheduled

Frequently Asked Questions

No FAQs available for this business.

Reviews

No reviews yet. Be the first to review!

Social Links

Photo Gallery

No photos available

Business Info

53
2017
$10.0M

Business Hours

Business hours not available

Own This Business?

Unclaimed

Take control of your business page to update information, respond to reviews, and more.

Claim This Business